NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.05 | -0.00 | 0.12 |
| FCF Yield | -45.42% | -78.29% | -54.55% | -5.83% |
| EV / EBITDA | -1.93 | -0.85 | -0.88 | -6.06 |
| Quality | ||||
| ROIC | -362.84% | 8,859.56% | -201.19% | -51.57% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 0.83 | 0.61 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -20.94% | -9.50% | -392.03% | -121.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | 0.26 | 0.27 | 3.20 |
| Interest Coverage | -31.84 | -21.91 | -903.47 | -4.84 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.02 | -0.02 |
| Cash Conversion Cycle | -19,245.45 | -5,490.05 | -17,126.29 | -26,401.67 |